Shares of Health Care sector company Moderna moved -1.5% today, and are now trading at a price of $122.37. The large-cap stock's daily volume was 340,822 compared to its average volume of 3,305,440. The S&P 500 index returned a -0.0% performance.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. The company is based in Cambridge and has 3,900 full time employees. Its market capitalization is $46,648,619,008.
15 analysts are following Moderna and have set target prices ranging from $82.0 to $430.0 per share. On average, they have given the company a rating of buy. At today's prices, MRNA is trading -43.33% away from its average analyst target price of $215.93 per share.
Over the last year, MRNA shares have gone down by -8.7%, which represents a difference of -25.0% when compared to the S&P 500. The stock's 52 week high is $217.25 per share and its 52 week low is $115.03. With average free cash flows of $4.85 Billion that have been growing at an average rate of 79.3% over the last 4 years, Moderna declining stock performance may not be reflective of the quality of its underlying business.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cashflow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | 4,981,000 | -400,000 | 4,581,000 | -65.65 |
| 2021-12-31 | 13,620,000 | -284,000 | 13,336,000 | 580.57 |
| 2020-12-31 | 2,026,971 | -67,448 | 1,959,523 | 499.48 |
| 2019-12-31 | -458,968 | -31,554 | -490,522 | n/a |
